{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:36:26Z","timestamp":1777905386165,"version":"3.51.4"},"reference-count":60,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Horizon Europe program and Norte 2020","award":["NORTE-01-0145-FEDER-000057"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000057"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Human papillomavirus (HPV)-related diseases are highly prevalent in men worldwide, comprising external anogenital condyloma, anal intraepithelial neoplasia (AIN), penile intraepithelial neoplasia (PIN), and anogenital and oropharyngeal cancers. There is exceptionally low vaccine coverage in the male population. Only 4% of men were fully vaccinated, worldwide, as of 2019. The aim of this review is to assess the impact of HPV vaccination on male disease. Three databases (MEDLINE, Web of Science, Scopus) and Clinical Trials.gov were searched. We included thirteen studies, eight randomized controlled trials (RCTs), and five cohorts, comprising a total of 14,239 participants. Regarding anal disease, seven studies reported HPV vaccine efficacy ranging from 91.1% to 93.1% against AIN1, and ranging from 89.6% to 91.7% against AIN2|3 and anal cancer. Five studies showed an efficacy against genital condyloma of 89.9% in HPV-na\u00efve males, varying between 66.7% and 67.2% in intention-to-treat populations. Studies reporting no efficacy have included older participants. These results support vaccination of young men previously infected, beyond HPV-na\u00efve males. The evidence quality was moderate to low for most outcomes, namely genital diseases. RCTs are needed to assess the efficacy of HPV vaccination on male oropharyngeal cancer.<\/jats:p>","DOI":"10.3390\/vaccines11061083","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T01:28:21Z","timestamp":1686533301000},"page":"1083","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Impact of Human Papillomavirus Vaccination on Male Disease: A Systematic Review"],"prefix":"10.3390","volume":"11","author":[{"given":"Catarina","family":"Rosado","sequence":"first","affiliation":[{"name":"Division of Microbiology, Department of Pathology, Faculty of Medicine, University of Porto, 4200-039 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8963-7053","authenticated-orcid":false,"given":"\u00c2ngela Rita","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Division of Microbiology, Department of Pathology, Faculty of Medicine, University of Porto, 4200-039 Porto, Portugal"}]},{"given":"Ac\u00e1cio Gon\u00e7alves","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Division of Microbiology, Department of Pathology, Faculty of Medicine, University of Porto, 4200-039 Porto, Portugal"},{"name":"CINTESIS@RISE, Center of Health Technology and Services Research\/Rede de Investiga\u00e7\u00e3o em Sa\u00fade, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8247-8902","authenticated-orcid":false,"given":"Carmen","family":"Lisboa","sequence":"additional","affiliation":[{"name":"Division of Microbiology, Department of Pathology, Faculty of Medicine, University of Porto, 4200-039 Porto, Portugal"},{"name":"CINTESIS@RISE, Center of Health Technology and Services Research\/Rede de Investiga\u00e7\u00e3o em Sa\u00fade, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"},{"name":"Department of Dermatology and Venereology, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1038\/s41598-021-83727-7","article-title":"Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: A systematic review and meta-analysis","volume":"11","author":"Zizza","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_2","first-page":"61","article-title":"HPV related diseases in males: A heavy vaccine-preventable burden","volume":"54","author":"Canepa","year":"2013","journal-title":"J. Prev. Med. Hyg."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Passos, M.R.L. (2018). Atlas of Sexually Transmitted Diseases: Clinical Aspects and Differential Diagnosis, Springer International Publishing.","DOI":"10.1007\/978-3-319-57470-7_11"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.ypmed.2011.08.002","article-title":"Genital HPV infection and related lesions in men","volume":"53","author":"Anic","year":"2011","journal-title":"Prev. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/14760584.2022.2008243","article-title":"Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: A systematic review of study designs and data sources","volume":"21","author":"Wang","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1080\/14760584.2022.2129615","article-title":"Real-world impact and effectiveness of the quadrivalent HPV vaccine: An updated systematic literature review","volume":"21","author":"Wang","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pvr.2016.01.001","article-title":"High specific immune response to a bivalent anti-HPV vaccine in HIV-1-infected men in S\u00e3o Paulo, Brazil","volume":"2","author":"Fontes","year":"2016","journal-title":"Papillomavirus Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"106592","DOI":"10.1016\/j.cct.2021.106592","article-title":"Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men","volume":"115","author":"Giuliano","year":"2022","journal-title":"Contemp. Clin. Trials"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1016\/j.vaccine.2016.06.056","article-title":"A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men","volume":"34","author":"Meijer","year":"2016","journal-title":"Vaccine"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Patel, H., Wagner, M., Singhal, P., and Kothari, S. (2013). Systematic review of the incidence and prevalence of genital warts. BMC Infect. Dis., 13.","DOI":"10.1186\/1471-2334-13-39"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.21149\/7824","article-title":"Human papillomavirus vaccine efficacy in the prevention of anogenital warts: Systematic review and meta-analysis","volume":"59","author":"Tejada","year":"2017","journal-title":"Salud Publica Mex."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/hed.25477","article-title":"MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis","volume":"41","year":"2019","journal-title":"Head Neck"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.rmed.2017.03.030","article-title":"Recurrent respiratory papillomatosis: A state-of-the-art review","volume":"126","author":"Fortes","year":"2017","journal-title":"Respir. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/jso.26687","article-title":"Epidemiology and incidence of HPV-related cancers of the head and neck","volume":"124","author":"Roman","year":"2021","journal-title":"J. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cncr.20364","article-title":"Anal cancer incidence and survival: The surveillance, epidemiology, and end results experience, 1973\u20132000","volume":"101","author":"Johnson","year":"2004","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/cid\/ciab434","article-title":"High Prevalence of Anal High-Grade Squamous Intraepithelial Lesions, and Prevention Through Human Papillomavirus Vaccination, in Young Men Who Have Sex with Men Living with Human Immunodeficiency Virus","volume":"73","author":"Palefsky","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/cid\/cir1036","article-title":"Prevention of Recurrent High-Grade Anal Neoplasia With Quadrivalent Human Papillomavirus Vaccination of Men Who Have Sex With Men: A Nonconcurrent Cohort Study","volume":"54","author":"Swedish","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: A review and synthetic analysis","volume":"13","author":"Ferlay","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.eururo.2015.12.007","article-title":"Role of Human Papillomavirus in Penile Carcinomas Worldwide","volume":"69","author":"Alemany","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience","volume":"63","author":"Garland","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"106399","DOI":"10.1016\/j.ypmed.2020.106399","article-title":"HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010\u20132019","volume":"144","author":"Bruni","year":"2021","journal-title":"Prev. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1136\/jech-2020-216305","article-title":"Cost-effectiveness of extending the HPV vaccination to boys: A systematic review","volume":"75","author":"Medina","year":"2021","journal-title":"J. Epidemiol. Community Health"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1089\/jayao.2019.0004","article-title":"A Systematic Literature Review of HPV Vaccination Barriers Among Adolescent and Young Adult Males","volume":"8","author":"Dibble","year":"2019","journal-title":"J. Adolesc. Young Adult Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Grandahl, M., and Nev\u00e9us, T. (2021). Barriers towards HPV Vaccinations for Boys and Young Men: A Narrative Review. Viruses, 13.","DOI":"10.3390\/v13081644"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s41256-022-00261-3","article-title":"Examining enablers of vaccine hesitancy toward routine childhood and adolescent vaccination in Malawi","volume":"7","author":"Adeyanju","year":"2022","journal-title":"Glob. Health Res. Policy"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., and Altman, D.G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/PGP.0b013e31826916c7","article-title":"The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: Background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology","volume":"32","author":"Darragh","year":"2013","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1016\/j.vaccine.2013.06.057","article-title":"Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males","volume":"31","author":"Goldstone","year":"2013","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/cid\/ciy274","article-title":"A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298","volume":"67","author":"Wilkin","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.vaccine.2019.01.069","article-title":"Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study","volume":"37","author":"Mikamo","year":"2019","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Hidalgo-Tenorio, C., Pasquau, J., Omar-Mohamed, M., Sampedro, A., L\u00f3pez-Ruz, M.A., L\u00f3pez Hidalgo, J., and Ram\u00edrez-Taboada, J. (2021). Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal \u2265 HSILs in a Spanish Population of HIV+ MSM Aged > 26 Years. Viruses, 13.","DOI":"10.3390\/v13020144"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1097\/QAD.0000000000002928","article-title":"HPV vaccination to prevent recurrence of anal intraepithelial neoplasia in HIV+ MSM","volume":"35","author":"Gosens","year":"2021","journal-title":"Aids"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1111\/jsm.12670","article-title":"Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: A randomized study","volume":"11","author":"Coskuner","year":"2014","journal-title":"J. Sex. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100203","DOI":"10.1016\/j.pvr.2020.100203","article-title":"Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up","volume":"10","author":"Olsson","year":"2020","journal-title":"Papillomavirus Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e657","DOI":"10.1542\/peds.2013-4144","article-title":"Long-term study of a quadrivalent human papillomavirus vaccine","volume":"134","author":"Ferris","year":"2014","journal-title":"Pediatrics"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1473-3099(21)00327-3","article-title":"Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: Results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Goldstone","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Swedish, K.A., and Goldstone, S.E. (2014). Prevention of Anal Condyloma with Quadrivalent Human Papillomavirus Vaccination of Older Men Who Have Sex with Men. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0093393"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1086\/604729","article-title":"Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003\u20132004","volume":"200","author":"Markowitz","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1158\/1055-9965.EPI-10-1160","article-title":"Human Papillomavirus (HPV) 6, 11, 16, and 18 Seroprevalence Is Associated with Sexual Practice and Age: Results from the Multinational HPV Infection in Men Study (HIM Study)","volume":"20","author":"Lu","year":"2011","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-3-030-03502-0_7","article-title":"HPV-Associated Anal Cancer in the HIV\/AIDS Patient","volume":"177","author":"Wang","year":"2018","journal-title":"Cancer Treat. Res."},{"key":"ref_46","first-page":"1","article-title":"Human papillomavirus vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_47","unstructured":"(2023, March 24). Guidance on HPV Vaccination in EU Countries: Focus on Boys, People Living with HIV and 9-Valent HPV Vaccine Introduction. Available online: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/guidance-hpv-vaccination-eu-focus-boys-people-living-hiv-9vHPV-vaccine."},{"key":"ref_48","first-page":"4153","article-title":"Analysis of persistence of human papillomavirus infection in men evaluated by sampling multiple genital sites","volume":"19","author":"Capra","year":"2015","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1080\/21645515.2015.1112474","article-title":"HPV vaccination for MSM: Synthesis of the evidence and recommendations from the Qu\u00e9bec Immunization Committee","volume":"12","author":"Sauvageau","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_50","first-page":"352","article-title":"HPV vaccination in boys and men: Update and recommendations","volume":"39","author":"Rossi","year":"2018","journal-title":"Rev. Med. Brux."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1002\/cncr.31035","article-title":"Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: Clinical effectiveness and cost-effectiveness","volume":"123","author":"Deshmukh","year":"2017","journal-title":"Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Grace, D., Gaspar, M., Paquette, R., Rosenes, R., Burchell, A.N., Grennan, T., and Salit, I.E. (2018). HIV-positive gay men\u2019s knowledge and perceptions of Human Papillomavirus (HPV) and HPV vaccination: A qualitative study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0207953"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Ejaz, M., Ekstr\u00f6m, A.M., Ahmed, A., Haroon, A., Ali, D., Ali, T.S., and Salazar, M. (2022). Human Papillomavirus associated prevention: Knowledge, attitudes, and perceived risks among men who have sex with men and transgender women in Pakistan: A qualitative study. BMC Public Health, 22.","DOI":"10.1186\/s12889-022-12775-z"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/jfd.13106","article-title":"Virucidal effects of various agents-including protease-against koi herpesvirus and viral haemorrhagic septicaemia virus","volume":"43","author":"Amtmann","year":"2020","journal-title":"J. Fish Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1177\/0956462419852224","article-title":"Safety and efficacy of human papillomavirus vaccination for people living with HIV: A systematic review and meta-analysis","volume":"30","author":"Zhan","year":"2019","journal-title":"Int. J. STD AIDS"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Harder, T., Wichmann, O., Klug, S.J., van der Sande, M.A.B., and Wiese-Posselt, M. (2018). Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: A systematic review. BMC Med., 16.","DOI":"10.1186\/s12916-018-1098-3"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2001659","DOI":"10.2807\/1560-7917.ES.2021.26.50.2001659","article-title":"Human papillomavirus vaccination in the European Union\/European Economic Area and globally: A moral dilemma","volume":"26","author":"Colzani","year":"2021","journal-title":"Eurosurveillance"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: Updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"key":"ref_59","first-page":"2111","article-title":"Inter-rater agreement and time to complete the new Cochrane Risk-of-Bias tool (RoB 2.0). Abstracts of the Global Evidence Summit, Cape Town, South Africa","volume":"9","author":"Minozzi","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13643-020-1271-6","article-title":"Inter-rater reliability and concurrent validity of ROBINS-I: Protocol for a cross-sectional study","volume":"9","author":"Jeyaraman","year":"2020","journal-title":"Syst. Rev."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/6\/1083\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:52:02Z","timestamp":1760125922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/6\/1083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":60,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["vaccines11061083"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11061083","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]}}}